NCT03713593 2026-02-05
LEAP-002
Merck Sharp & Dohme LLC
Phase 3 Completed
Clinical Trials
73 trialsNCT03867084 2026-02-04
KEYNOTE-937
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01730937 2026-01-28
Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT04157985 2025-12-11
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
Phase 3 Completed
NCT03412773 2025-10-14
A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
BeiGene
Phase 3 Completed
NCT02799212 2025-10-03
SOMAPROTECT01
Hospices Civils de Lyon
Phase 3 Completed
NCT03062358 2025-09-30
MK-3475-394
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04487067 2025-09-22
AMETHISTA
Hoffmann-La Roche
Phase 3 Completed
NCT02764801 2025-05-06
Contrast-enhanced Ultrasound Evaluation of Chemoembolization
Thomas Jefferson University
Phase 3 Completed
NCT02576509 2025-02-17
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
Bristol-Myers Squibb
Phase 3 Completed
NCT01906216 2024-08-28
SELECT
Air Force Military Medical University, China
Phase 3 Completed
NCT02112656 2024-08-20
OPTIMA
Imunon
Phase 3 Completed
NCT02856126 2024-07-23
HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC
Sun Yat-sen University
Phase 3 Completed
NCT04047173 2024-06-17
RFA Versus SBRT for Recurrent Small HCC
Sun Yat-sen University
Phase 3 Completed
NCT02109146 2024-05-29
Postoperative TACE(Transhepatic Arterial Chemotherapy And Embolization) for Patients With Hepatocellular Carcinoma
Zhejiang University
Phase 3 Completed
NCT00617981 2024-05-03
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
Imunon
Phase 3 Completed
NCT04103398 2024-02-28
TREAT
Sun Yat-sen University
Phase 3 Completed
NCT02650271 2024-01-23
Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC
Guangxi Medical University
Phase 3 Completed
NCT02329860 2024-01-22
Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT01004978 2024-01-03
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT03434379 2023-10-23
IMbrave150
Hoffmann-La Roche
Phase 3 Completed
NCT00699816 2023-07-11
Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients
GC Cell Corporation
Phase 3 Completed
NCT02973685 2023-06-12
HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.
Sun Yat-sen University
Phase 3 Completed
NCT02438436 2023-01-30
SD/GC-HCC
Guangxi Medical University
Phase 3 Completed
NCT02435433 2023-01-20
REACH-2
Eli Lilly and Company
Phase 3 Completed
NCT01015833 2022-08-04
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT01761266 2022-04-05
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
Eisai Inc.
Phase 3 Completed
NCT01655693 2021-06-02
ReLive
Valerio Therapeutics
Phase 3 Completed
NCT01908426 2021-05-06
CELESTIAL
Exelixis
Phase 3 Completed
NCT02562755 2020-12-16
PHOCUS
SillaJen, Inc.
Phase 3 Completed
NCT03164382 2020-12-16
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Phase 3 Completed
NCT00016380 2020-04-03
Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen
Canadian Cancer Trials Group
Phase 3 Completed
NCT01833299 2020-02-11
Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma
Sun Yat-sen University
Phase 3 Completed
NCT02774187 2019-12-05
Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC
Sun Yat-sen University
Phase 3 Completed
NCT00908752 2019-12-02
BRISK TA
Bristol-Myers Squibb
Phase 3 Completed
NCT01287585 2019-09-06
ADI-PEG 20
Polaris Group
Phase 3 Completed
NCT01229839 2019-03-06
Chemoembolization With or Without Mixing the Chemotherapy With Lipiodol for Unresectable HCC
Sun Yat-sen University
Phase 3 Completed
NCT01259414 2019-03-06
Comparison of Two Solvents Used With Chemotherapy Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma
Sun Yat-sen University
Phase 3 Completed
NCT03636620 2018-08-17
TACE+RFA
Fudan University
Phase 3 Completed
NCT00692770 2018-08-08
STORM
Bayer
Phase 3 Completed
NCT01265810 2017-11-13
COMTT
Impaqtt Foundation
Phase 3 Completed
NCT00759109 2017-04-07
Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01804829 2017-03-15
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
Biotest Pharmaceuticals Corporation
Phase 3 Completed
NCT01313377 2017-01-25
Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery
UNICANCER
Phase 3 Completed
NCT01482442 2017-01-16
SARAH
Assistance Publique - Hôpitaux de Paris
Phase 3 Completed
NCT01035229 2016-09-22
EVOLVE-1
Novartis
Phase 3 Completed
NCT02788526 2016-06-20
Adjuvant TACE to Reduce the HCC Recurrence After Resection
Sun Yat-sen University
Phase 3 Completed
NCT00769106 2016-04-14
HCC-CIK
Sun Yat-sen University
Phase 3 Completed
NCT01749865 2016-04-14
CIK Treatment for HCC Patient Underwent Radical Resection
Sun Yat-sen University
Phase 3 Completed
NCT00241020 2016-04-12
Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma
Novartis
Phase 3 Completed